Chin-Hsiao Tseng1. 1. Department of Internal Medicine, National Taiwan University College of Medicine, Taipei, Taiwan. ccktsh@ms6.hinet.net
Abstract
BACKGROUND: Whether rosiglitazone may increase bladder cancer risk has not been extensively investigated. METHODS: The reimbursement databases of all Taiwanese diabetic patients under oral anti-diabetic agents or insulin from 1996 to 2009 were retrieved from the National Health Insurance. An entry date was set at 1 January 2006 and a total of 885,236 patients with type 2 diabetes were followed up for bladder cancer incidence till end of 2009. Incidences for ever-users, never-users and subgroups of rosiglitazone exposure (using tertile cutoffs of time since starting rosiglitazone, duration of therapy and cumulative dose) were calculated and hazard ratios estimated by Cox regression. RESULTS: There were 102,926 ever-users and 782,310 never-users, respective numbers of incident bladder cancer 356 (0.35%) and 2753 (0.35%), and respective incidence 98.3 and 101.6 per 100,000 person-years. The overall hazard ratios (95% confidence intervals) did not show significant association in unadjusted model [0.969 (0.867, 1.082)] and models adjusted for age and sex [0.983 (0.880, 1.098)] or all covariates [0.980 (0.870, 1.104)]. Neither the P values for the hazard ratios for the different categories of the dose-responsive parameters, nor their P-trends were significant. CONCLUSIONS: Rosiglitazone does not increase the risk of bladder cancer.
BACKGROUND: Whether rosiglitazone may increase bladder cancer risk has not been extensively investigated. METHODS: The reimbursement databases of all Taiwanese diabeticpatients under oral anti-diabetic agents or insulin from 1996 to 2009 were retrieved from the National Health Insurance. An entry date was set at 1 January 2006 and a total of 885,236 patients with type 2 diabetes were followed up for bladder cancer incidence till end of 2009. Incidences for ever-users, never-users and subgroups of rosiglitazone exposure (using tertile cutoffs of time since starting rosiglitazone, duration of therapy and cumulative dose) were calculated and hazard ratios estimated by Cox regression. RESULTS: There were 102,926 ever-users and 782,310 never-users, respective numbers of incident bladder cancer 356 (0.35%) and 2753 (0.35%), and respective incidence 98.3 and 101.6 per 100,000 person-years. The overall hazard ratios (95% confidence intervals) did not show significant association in unadjusted model [0.969 (0.867, 1.082)] and models adjusted for age and sex [0.983 (0.880, 1.098)] or all covariates [0.980 (0.870, 1.104)]. Neither the P values for the hazard ratios for the different categories of the dose-responsive parameters, nor their P-trends were significant. CONCLUSIONS:Rosiglitazone does not increase the risk of bladder cancer.
Authors: Richard M Turner; Chun S Kwok; Chen Chen-Turner; Chinedu A Maduakor; Sonal Singh; Yoon K Loke Journal: Br J Clin Pharmacol Date: 2014-08 Impact factor: 4.335
Authors: Francesco Salvo; Fabienne Bazin; Aude Kostrzewa; Christian Bandre; Philip Robinson; Nicholas Moore; Bernard Bégaud; Antoine Pariente Journal: Drug Saf Date: 2014-05 Impact factor: 5.606
Authors: Daniel Levin; Samira Bell; Reijo Sund; Sirpa A Hartikainen; Jaakko Tuomilehto; Eero Pukkala; Ilmo Keskimäki; Ellena Badrick; Andrew G Renehan; Iain E Buchan; Samantha L Bowker; Jasjeet K Minhas-Sandhu; Zafar Zafari; Carlo Marra; Jeffrey A Johnson; Bruno H Stricker; Andrè G Uitterlinden; Albert Hofman; Rikje Ruiter; Catherine E de Keyser; Thomas M MacDonald; Sarah H Wild; Paul M McKeigue; Helen M Colhoun Journal: Diabetologia Date: 2014-12-07 Impact factor: 10.122